Furthermore, rapamycin treatment improves the capacity of DCs to augment the induction of primary antigen-specific CD8+ T cell responses and induces effective anti-tumor responses by inducing efficient and sustained CTL responses in a therapeutic vaccination treatment model (162). Here, CD8A is linked to neoplasm.